Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm by Site — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site

Other

Neoplasm by Site

CI-CAN-00000003Explore in graph →

Non-malignant20,494 active trials253 approved drugs3,567 evidence items

NCIt: C3263
MeSH: D009371

Overview
Statistics
Survival
Genomics477
Variants & evidence3567
Drugs398
Trials92594
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,275)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,726–3,750 of 4,275 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.
· Carcinogenesis · 2006 · PMID 16338952 · validated civic_curation pubmed
Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.
· Cancer Biol Ther · 2014 · PMID 24642870 · validated civic_curation pubmed
Modeling alveolar soft part sarcomagenesis in the mouse: a role for lactate in the tumor microenvironment.
· Cancer Cell · 2014 · PMID 25453902 · validated civic_curation pubmed
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
· Proc Natl Acad Sci U S A · 2012 · PMID 23236167 · validated civic_curation pubmed
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
· Oncotarget · 2017 · PMID 28077790 · validated civic_curation pubmed
A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-κB.
· Cell Rep · 2018 · PMID 29949764 · validated civic_curation pubmed
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
· Cancer Res · 2009 · PMID 19244107 · validated civic_curation pubmed

Showing 3,726–3,750 of 4,275 publications

← Previous
1
…
149
150
151
…
171
Next →

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.

· Cancer Res · 2009 · PMID 19117982 · validated civic_curation pubmed

The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice.

· Oncogene · 2000 · PMID 10828883 · validated civic_curation pubmed

Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs.

· J Clin Invest · 2024 · PMID 38687617 · validated civic_curation pubmed

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.

· ACS Med Chem Lett · 2018 · PMID 29670690 · validated civic_curation pubmed

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

· Cancer Res · 2010 · PMID 20570890 · validated civic_curation pubmed

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

· Cancer Cell · 2008 · PMID 18394554 · validated civic_curation pubmed

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

· Cancer Cell · 2011 · PMID 21575866 · validated civic_curation pubmed

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

· Clin Cancer Res · 2011 · PMID 21948233 · validated civic_curation pubmed

Anti-tumor activity of motesanib in a medullary thyroid cancer model.

· J Endocrinol Invest · 2012 · PMID 21422803 · validated civic_curation pubmed

AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.

· PLoS One · 2012 · PMID 23056499 · validated civic_curation pubmed

A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.

· Cancer Cell · 2013 · PMID 23845441 · validated civic_curation pubmed

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

· Cancer Res · 2012 · PMID 22180495 · validated civic_curation pubmed

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

· Sci Transl Med · 2011 · PMID 22072639 · validated civic_curation pubmed

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).

· Blood · 2005 · PMID 15626738 · validated civic_curation pubmed

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

· J Clin Oncol · 2008 · PMID 18202412 · validated civic_curation pubmed

Identification of targetable FGFR gene fusions in diverse cancers.

· Cancer Discov · 2013 · PMID 23558953 · validated civic_curation pubmed

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.

· Blood · 2011 · PMID 21719597 · validated civic_curation pubmed

TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.

· Oncogene · 2010 · PMID 19966866 · validated civic_curation pubmed